{"ticker": {"uuid": "6bdf4718-47f6-4d60-8418-df34655523a9", "symbol": "GSK", "name": "GlaxoSmithKline PLC ADR", "exchange": "NYSE", "country": "US", "sector": "Healthcare", "industry": "Drug Manufacturers - General"}, "articles": [{"title": "Spero Therapeutics and GSK Announce FDA Approval of Utebzi, the First Oral Carbapenem Antibiotic for Complicated Urinary Tract Infections in the US", "summary": "Spero Therapeutics and GSK have received FDA approval for Utebzi, the first oral carbapenem antibiotic for complicated urinary tract infections (cUTIs) in adults. This approval addresses a significant treatment gap, particularly for patients with limited oral treatment options, a", "url": "https://www.quiverquant.com/news/Spero+Therapeutics+and+GSK+Announce+FDA+Approval+of+Utebzi%2C+the+First+Oral+Carbapenem+Antibiotic+for+Complicated+Urinary+Tract+Infections+in+the+US", "source_name": "Quiver Quantitative", "published_at": "2026-06-17T17:09:17", "published_display": "17 Jun 2026 17:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA clears GSK (NYSE: GSK) oral antibiotic for complicated UTIs", "summary": "GSK announced that the FDA has approved Utebzi (tebipenem pivoxil), the first and only oral carbapenem antibiotic for adults with complicated urinary tract infections (cUTIs), including pyelonephritis, who have limited or no alternative oral options. This approval is based on the", "url": "https://www.stocktitan.net/sec-filings/GSK/6-k-gsk-plc-current-report-foreign-issuer-7d3b9509602f.html", "source_name": "Stock Titan", "published_at": "2026-06-17T16:09:17", "published_display": "17 Jun 2026 16:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GSK\u2019s momelotinib granted Orphan Drug Designations in the US and EU for VEXAS syndrome", "summary": "GSK announced that momelotinib, a JAK inhibitor, has received Orphan Drug Designation", "url": "https://www.gsk.com/en-gb/media/press-releases/gsk-s-momelotinib-granted-orphan-drug-designations-in-the-us-and-eu-for-vexas-syndrome/", "source_name": "GSK", "published_at": "2026-06-13T06:40:44", "published_display": "13 Jun 2026 06:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GSK receives US and EU orphan drug designations for momelotinib in VEXAS syndrome", "summary": "GSK announced that its drug momelotinib received Orphan Drug Designation from both the US FDA and the European Medicines Agency for VEXAS syndrome, a rare and progressive blood disorder with high mortality and no approved treatments. These designations are supported by case studi", "url": "https://m.investing.com/news/sec-filings/gsk-receives-us-and-eu-orphan-drug-designations-for-momelotinib-in-vexas-syndrome-93CH-4739291?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-12T11:09:17", "published_display": "12 Jun 2026 11:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GSK (NYSE: GSK) wins US and EU orphan designations for VEXAS drug", "summary": "GSK has received Orphan Drug Designation from both the US FDA and European Medicines Agency (EMA) for its JAK inhibitor momelotinib, intended to treat VEXAS syndrome. VEXAS is a rare, life-threatening haemato-inflammatory disorder with high mortality and no approved treatments. T", "url": "https://www.stocktitan.net/sec-filings/GSK/6-k-gsk-plc-current-report-foreign-issuer-00295f6d4c35.html", "source_name": "Stock Titan", "published_at": "2026-06-12T10:40:12", "published_display": "12 Jun 2026 10:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GSK US President Acquires Notional ADS Under Executive Savings Plan", "summary": "GSK's U.S. President, Maya Martinez-Davis, acquired notional American Depositary Shares (ADS) through her executive savings plan on June 8, 2026, signaling confidence in the company's equity performance and long-term prospects. This comes as TipRanks\u2019 AI Analyst, Spark, rates GSK", "url": "https://www.tipranks.com/news/company-announcements/gsk-us-president-acquires-notional-ads-under-executive-savings-plan", "source_name": "TipRanks", "published_at": "2026-06-10T14:09:40", "published_display": "10 Jun 2026 14:09", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[6-K] GSK plc Current Report (Foreign Issuer) | GSK SEC Filing - Form 6-K", "summary": "GSK plc filed a Form 6-K report with the SEC, detailing a transaction involving Maya Martinez-Davis, President, US. The report indicates an initial notification for the acquisition of notional American Depositary Shares (ADS) within her GSK Executive Supplemental Savings Plan acc", "url": "https://www.stocktitan.net/sec-filings/GSK/6-k-gsk-plc-current-report-foreign-issuer-fca69a802394.html", "source_name": "Stock Titan", "published_at": "2026-06-10T14:09:40", "published_display": "10 Jun 2026 14:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GSK to buy Nuvalent for $10.6B (GSK:NYSE)", "summary": "GSK has announced an agreement to acquire Nuvalent, a U.S. biopharmaceutical company, for approximately $10.6 billion. GSK plans to initiate a tender offer within ten business days to acquire all outstanding Nuvalent Class A and Class B shares.", "url": "https://seekingalpha.com/news/4601644-gsk-to-buy-nuvalent-for-106b", "source_name": "Seeking Alpha", "published_at": "2026-06-09T03:02:00", "published_display": "09 Jun 2026 03:02", "sentiment": "positive", "sentiment_pct": 69, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GlaxoSmithKline stock forecast | Is GSK a Good Stock to Buy?", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPdTAtU25VbHVMcHo1TkFxRWg3S2NBZUlrdkQyU1hJbDFWRjVPU2c0Y1NhdkdVZkQ2MmNfV3F6T2E4LTF4dkw2WDlzRVd1LWFiYllOUmZ5YkpfWTJpaXdQdXNPU1JVTENHWDBLc3RNdUxPQnJBeEFrdl9VSEY3NlBRcg?oc=5", "source_name": "Capital.com", "published_at": "2025-08-28T07:00:00+00:00", "published_display": "28 Aug 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Spero Therapeutics and GSK Announce FDA Approval of Utebzi, the First Oral Carbapenem Antibiotic for Complicated Urinary Tract Infections in the US", "summary": "Spero Therapeutics and GSK have received FDA approval for Utebzi, the first oral carbapenem antibiotic for complicated urinary tract infections (cUTIs) in adults. This approval addresses a significant treatment gap, particularly for patients with limited oral treatment options, a", "url": "https://www.quiverquant.com/news/Spero+Therapeutics+and+GSK+Announce+FDA+Approval+of+Utebzi%2C+the+First+Oral+Carbapenem+Antibiotic+for+Complicated+Urinary+Tract+Infections+in+the+US", "source_name": "Quiver Quantitative", "published_at": "2026-06-17T17:09:17", "published_display": "17 Jun 2026 17:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA clears GSK (NYSE: GSK) oral antibiotic for complicated UTIs", "summary": "GSK announced that the FDA has approved Utebzi (tebipenem pivoxil), the first and only oral carbapenem antibiotic for adults with complicated urinary tract infections (cUTIs), including pyelonephritis, who have limited or no alternative oral options. This approval is based on the", "url": "https://www.stocktitan.net/sec-filings/GSK/6-k-gsk-plc-current-report-foreign-issuer-7d3b9509602f.html", "source_name": "Stock Titan", "published_at": "2026-06-17T16:09:17", "published_display": "17 Jun 2026 16:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GSK\u2019s momelotinib granted Orphan Drug Designations in the US and EU for VEXAS syndrome", "summary": "GSK announced that momelotinib, a JAK inhibitor, has received Orphan Drug Designation", "url": "https://www.gsk.com/en-gb/media/press-releases/gsk-s-momelotinib-granted-orphan-drug-designations-in-the-us-and-eu-for-vexas-syndrome/", "source_name": "GSK", "published_at": "2026-06-13T06:40:44", "published_display": "13 Jun 2026 06:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GSK receives US and EU orphan drug designations for momelotinib in VEXAS syndrome", "summary": "GSK announced that its drug momelotinib received Orphan Drug Designation from both the US FDA and the European Medicines Agency for VEXAS syndrome, a rare and progressive blood disorder with high mortality and no approved treatments. These designations are supported by case studi", "url": "https://m.investing.com/news/sec-filings/gsk-receives-us-and-eu-orphan-drug-designations-for-momelotinib-in-vexas-syndrome-93CH-4739291?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-12T11:09:17", "published_display": "12 Jun 2026 11:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GSK (NYSE: GSK) wins US and EU orphan designations for VEXAS drug", "summary": "GSK has received Orphan Drug Designation from both the US FDA and European Medicines Agency (EMA) for its JAK inhibitor momelotinib, intended to treat VEXAS syndrome. VEXAS is a rare, life-threatening haemato-inflammatory disorder with high mortality and no approved treatments. T", "url": "https://www.stocktitan.net/sec-filings/GSK/6-k-gsk-plc-current-report-foreign-issuer-00295f6d4c35.html", "source_name": "Stock Titan", "published_at": "2026-06-12T10:40:12", "published_display": "12 Jun 2026 10:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GSK US President Acquires Notional ADS Under Executive Savings Plan", "summary": "GSK's U.S. President, Maya Martinez-Davis, acquired notional American Depositary Shares (ADS) through her executive savings plan on June 8, 2026, signaling confidence in the company's equity performance and long-term prospects. This comes as TipRanks\u2019 AI Analyst, Spark, rates GSK", "url": "https://www.tipranks.com/news/company-announcements/gsk-us-president-acquires-notional-ads-under-executive-savings-plan", "source_name": "TipRanks", "published_at": "2026-06-10T14:09:40", "published_display": "10 Jun 2026 14:09", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[6-K] GSK plc Current Report (Foreign Issuer) | GSK SEC Filing - Form 6-K", "summary": "GSK plc filed a Form 6-K report with the SEC, detailing a transaction involving Maya Martinez-Davis, President, US. The report indicates an initial notification for the acquisition of notional American Depositary Shares (ADS) within her GSK Executive Supplemental Savings Plan acc", "url": "https://www.stocktitan.net/sec-filings/GSK/6-k-gsk-plc-current-report-foreign-issuer-fca69a802394.html", "source_name": "Stock Titan", "published_at": "2026-06-10T14:09:40", "published_display": "10 Jun 2026 14:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GSK to buy Nuvalent for $10.6B (GSK:NYSE)", "summary": "GSK has announced an agreement to acquire Nuvalent, a U.S. biopharmaceutical company, for approximately $10.6 billion. GSK plans to initiate a tender offer within ten business days to acquire all outstanding Nuvalent Class A and Class B shares.", "url": "https://seekingalpha.com/news/4601644-gsk-to-buy-nuvalent-for-106b", "source_name": "Seeking Alpha", "published_at": "2026-06-09T03:02:00", "published_display": "09 Jun 2026 03:02", "sentiment": "positive", "sentiment_pct": 69, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GlaxoSmithKline stock forecast | Is GSK a Good Stock to Buy?", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPdTAtU25VbHVMcHo1TkFxRWg3S2NBZUlrdkQyU1hJbDFWRjVPU2c0Y1NhdkdVZkQ2MmNfV3F6T2E4LTF4dkw2WDlzRVd1LWFiYllOUmZ5YkpfWTJpaXdQdXNPU1JVTENHWDBLc3RNdUxPQnJBeEFrdl9VSEY3NlBRcg?oc=5", "source_name": "Capital.com", "published_at": "2025-08-28T07:00:00+00:00", "published_display": "28 Aug 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 90, "total_relevant": 9, "sentiment_summary": {"positive": 7, "negative": 0, "neutral": 2, "score": 65, "total": 9, "label": "Constructive news tone", "tone": "positive"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 74, "events": [{"event": "general", "label": "Market update", "weight": 2.55, "count": 4}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 7, "negative_events": 0}, "market_context": {"has_market_context": true, "latest_close": 50.67, "latest_week": "2026-06-19", "one_week_move": -4.5, "four_week_move": -1.4, "twelve_week_move": -5.1, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.957345, "market_dynamics_buy_signal": false, "relative_strength": -2.773232, "fair_value_gap": 29.0, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "positive", "expectation_probability": 56.1958, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-4.5% over one week, -1.4% over four weeks, trend inactive, and materially above fair value."}, "interpretation": {"label": "Positive news being faded", "tone": "negative", "classification": "positive_rejected", "summary": "Constructive headlines are not being rewarded by price, which raises a rejection flag.", "confidence": 74, "badges": ["Sentiment-trend disagreement", "Positive but stretched"], "opportunities": [], "risks": ["Positive news is arriving while the Sharemaestro trend signal is inactive.", "Constructive tone is arriving with price materially above fair value."], "event_label": "Market update", "sentiment_word": "constructive"}, "charts": {"sources": [{"label": "Stock Titan", "count": 3}, {"label": "Quiver Quantitative", "count": 1}, {"label": "GSK", "count": 1}, {"label": "Investing.com", "count": 1}, {"label": "TipRanks", "count": 1}, {"label": "Seeking Alpha", "count": 1}, {"label": "Capital.com", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 9}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 4}, {"label": "Regulatory and legal", "count": 2}, {"label": "Analyst action", "count": 1}, {"label": "Deals and strategy", "count": 1}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "65/100", "tone": "positive", "text": "Constructive news tone"}, {"label": "Market reaction", "value": "Positive news being faded", "tone": "negative", "text": "Constructive headlines are not being rewarded by price, which raises a rejection flag."}, {"label": "Primary event", "value": "Market update", "tone": "positive", "text": "74/100 classification confidence."}, {"label": "Company focus", "value": "9", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-4.5% over one week, -1.4% over four weeks, trend inactive, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Spero Therapeutics and GSK Announce FDA Approval of Utebzi, the First Oral Carbapenem Antibiotic for Complicated Urinary Tract Infections in the US"}], "updated_at": "2026-06-22T15:07:11.190718+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}